# Exploratory Study to Evaluate the Effect of SYN111 (Rufinamide) in Patients With Generalized Anxiety Disorder (GAD)

> **NCT00595231** · PHASE2 · COMPLETED · sponsor: **Biotie Therapies Inc.** · enrollment: 239 (actual)

## Conditions studied

- Generalized Anxiety Disorder

## Interventions

- **DRUG:** SYN111
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00595231
- **Lead sponsor:** Biotie Therapies Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03
- **Primary completion:** 2008-10
- **Final completion:** 2008-10
- **Target enrollment:** 239 (ACTUAL)
- **Last updated:** 2019-02-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00595231

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00595231, "Exploratory Study to Evaluate the Effect of SYN111 (Rufinamide) in Patients With Generalized Anxiety Disorder (GAD)". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00595231. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*